Immunosuppression News and Research

RSS

Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

Veloxis Pharmaceuticals seeks FDA approval to market Envarsus for prevention of organ rejection

Veloxis Pharmaceuticals A/S, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Envarsus (formerly LCP-Tacro) for the prevention of organ rejection in kidney transplant recipients.

30 Dec 2013

U.S. FDA grants Veloxis Orphan Drug status for Envarsus

Veloxis Pharmaceuticals A/S, today announced that Envarsus was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants.

24 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

In mice with a rodent form of multiple sclerosis (MS), vitamin D appears to block damage-causing immune cells from migrating to the central nervous system, offering a potential explanation for why the so-called "sunshine vitamin" may prevent or ease symptoms of the neurodegenerative disease, according to results of a study at Johns Hopkins.

9 Dec 2013

UCI MIND researchers receive grant to develop and study patient-derived stem cell lines

Researchers at UC Irvine's Institute for Memory Impairments and Neurological Disorders have received a two-year, $600,000 grant from the National Institute on Aging to develop and study patient-derived stem cell lines.

9 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression

Successful gene therapy is based on the effective delivery and maintained expression of healthy copies of a gene into tissues of individuals with a disease-associated genetic mutation.

16 Nov 2013

Researchers discovers key genetic culprit responsible for growth, metastasis of colon cancer

Chronic inflammation has long been known as a key risk factor for cancer---particularly colon cancer---but the exact mechanisms of how inflammation heightens the immune response, and ultimately influences the initiation and progression of cancer have remained elusive.

12 Nov 2013

UC researchers receive FDA grant to study generic tacrolimus in high-risk transplant patients

Transplant researchers at the University of Cincinnati have received a grant from the U.S. Food and Drug Administration to study the safety and efficacy of a generic immunosuppressive drug in high-risk transplant patients.

7 Nov 2013

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalationin involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.

29 Oct 2013

HIV-positive patients with high CD4 cell counts are not at increased risk for heart attacks

Patients who are HIV-positive and have high CD4 cell counts - or have a high number of white blood cells that fight infections - aren't at an increased risk for heart attacks compared to patients who are HIV-negative, according to a Kaiser Permanente study that appears in the current online issue of the Journal of Acquired Immune Deficiency Syndromes.

25 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Combining gene therapy with stem cells leads to faster healing of burns

Johns Hopkins researchers, working with elderly mice, have determined that combining gene therapy with an extra boost of the same stem cells the body already uses to repair itself leads to faster healing of burns and greater blood flow to the site of the wound.

10 Oct 2013

HIV infection heralds worse outcomes in NSCLC

Infection with HIV is an indicator of poor prognosis in patients with non-small-cell lung cancer, analysis of epidemiologic data indicates.

9 Oct 2013

Three Penn Medicine researchers awarded grants for neuromuscular disease research

The Muscular Dystrophy Association has awarded research grants totaling over $1,000,000 to three Penn Medicine researchers: James Shorter, PhD, associate professor of Biochemistry and Biophysics; Hansell Stedman, MD, associate professor of Surgery; and Lee Sweeney, PhD, director of the Center for Orphan Disease Research and Therapy.

9 Oct 2013

Researchers develop renal risk index to predict post-transplant end-stage renal disease

End-stage renal disease is one of the major public health problems among solid organ transplant recipients that is associated with death after transplant and high cost of care.

2 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

New gonorrhea treatment eliminates gonococcal infection from female mice

A new gonorrhea treatment, based on an anti-cancer therapy developed by a Buffalo startup company, has successfully eliminated gonococcal infection from female mice and prevented reinfection, according to research published today by University at Buffalo scientists in the Journal of Infectious Diseases.

19 Sep 2013